Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience

References

• Parisi R, Symmons DPM, Griffiths CEM, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–385.
   PubMed Web of Science ®Google Scholar
• Farley E, Menter A. Psoriasis: comorbidities and associations. G Ital Dermatol E Venereol Organo Uff Soc Ital Dermatol E Sifilogr. 2011;146:9–15.
   PubMed Web of Science ®Google Scholar
• Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 national psoriasis foundation patient-membership survey. Arch Dermatol. 2001;137:280–284.
   PubMed Web of Science ®Google Scholar
• Balato A, Scala E, Balato N, et al. Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders. Expert Opin Biol Ther. 2017;17:1363–1374.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6:383–392.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31:774–790.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Del Giglio M, Girolomoni G. Treatment approaches to moderate to severe psoriasis. Int J Mol Sci. 2017;18(11). pii: E2427. doi: 10.3390/ijms18112427.
   Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet Lond Engl. 2008;371:1665–1674.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet Lond Engl. 2008;371:1675–1684.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Papp KA, Wasfi Y, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol JEADV. 2013;27:1535–1545.
   PubMed Web of Science ®Google Scholar
• Young MS, Horn EJ, Cather JC. The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients. Expert Rev Clin Immunol. 2011;7:9–13.
   PubMed Web of Science ®Google Scholar
• Elberdín L, Fernández-Torres RM, Paradela S, et al. Ustekinumab treatment for moderate to severe psoriasis. Eight-year real-world follow-up of 61 cases in a tertiary level hospital. J Dermatol Treat. 2019;1–4. doi: 10.1080/09546634.2019.1605140. Epub ahead of print.
   PubMedGoogle Scholar
• van den Reek JMPA, Kievit W, Gniadecki R, et al. Drug survival studies in dermatology: principles,purposes, and pitfalls. J Invest Dermatol. 2015;135:1–5.
   PubMed Web of Science ®Google Scholar
• Strober BE, Bissonnette R, Fiorentino D, et al. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). J Am Acad Dermatol. 2016;74:851–861.e4.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Iversen L, Gniadecki R, et al. Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registry. J Eur Acad Dermatol Venereol JEADV. 2017;31:1183–1187.
   PubMed Web of Science ®Google Scholar
• Lin P-T, Wang S-H, Chi C-C. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. Sci Rep. [Internet]. 2018;8. [cited 2019 Feb 18]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207685/
   Web of Science ®Google Scholar
• No DJ, Inkeles MS, Amin M, et al. Drug survival of biologic treatments in psoriasis: a systematic review. J Dermatol Treat. 2018;29:460–466.
   PubMed Web of Science ®Google Scholar
• Warren RB, Brown BC, Lavery D, et al. Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre. Br J Dermatol. 2009;160:162–169.
   PubMed Web of Science ®Google Scholar
• Warren RB, Brown BC, Lavery D, et al. Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre. Br J Dermatol. 2010;163:859–862.
   PubMed Web of Science ®Google Scholar
• Laws PM, Downs AM, Parslew R, et al. Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland. Br J Dermatol. 2012;166:189–195.
   PubMed Web of Science ®Google Scholar
• Fernández-Torres RM, Paradela S, Fonseca E. Long-term response to etanercept monotherapy in moderate to severe psoriasis: assessment in daily practice by the maintenance of low values of PASI and BSA. J Dermatol Treat. 2014;25:54–56.
   PubMed Web of Science ®Google Scholar
• Papp KA, Fonjallaz P, Casset-Semanaz F, et al. Approaches to reporting long-term data. Curr Med Res Opin. 2008;24:2001–2008.
   PubMed Web of Science ®Google Scholar
• Hyrich KL, Symmons DPM, Silman AJ, et al. Reconciling subject differences in recruitment to clinical trials and clinical practice. J Rheumatol. 2005;32:2475–2476.
   PubMed Web of Science ®Google Scholar
• Zweegers J, Groenewoud JMM, van den Reek JMPA, et al. Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry. Br J Dermatol. 2017;176:1001–1009.
   PubMed Web of Science ®Google Scholar
• Warren RB, Smith CH, Yiu ZZN, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British association of dermatologists biologic interventions register (BADBIR). J Invest Dermatol. 2015;135:2632–2640.
   PubMed Web of Science ®Google Scholar
• Talamonti M, Galluzzo M, van den Reek JM, et al. Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients. Br J Dermatol. 2017;177:489–496.
   PubMed Web of Science ®Google Scholar
• Talamonti M, Galluzzo M, Chimenti S, et al. HLA-C*06 and response to ustekinumab in caucasian patients with psoriasis: outcome and long-term follow-up. J Am Acad Dermatol. 2016;74:374–375.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Boca AN, Botti E, et al. IL12B (p40) gene polymorphisms contribute to ustekinumab response prediction in psoriasis. Dermatol Basel Switz. 2016;232:230–236.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, D’Adamio S, Bianchi L, et al. Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab. J Dermatol Treat. 2019;30:40–44.
   PubMed Web of Science ®Google Scholar
• Saraceno R, Talamonti M, Galluzzo M, et al. Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases. Case Rep Dermatol. 2013;5:254–259.
   PubMedGoogle Scholar
• Di Stefani A, Galluzzo M, Talamonti M, et al. Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris. J Dermatol Case Rep. 2013;7:5–9.
   PubMedGoogle Scholar
• Galluzzo M, D’Adamio S, Chimenti MS, et al. Successful treatment of psoriatic crumbly nails with ustekinumab. Dermatol Ther. 2019;32:e12914.
   PubMed Web of Science ®Google Scholar
• Kulig P, Musiol S, Freiberger SN, et al. IL-12 protects from psoriasiform skin inflammation. Nat Commun. 2016;7:13466.
   PubMed Web of Science ®Google Scholar
• Cao X, Leonard K, Collins LI, et al. Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance. Cancer Res. 2009;69:8700–8709.
   PubMed Web of Science ®Google Scholar
• Garcia K, Sun Z, Mattson E, et al. IL-12 is required for mTOR regulation of memory CTLs during viral infection. Genes Immun. 2014;15:413–423.
   PubMed Web of Science ®Google Scholar
• Haraguchi S, Day NK, Nelson RP, et al. Interleukin 12 deficiency associated with recurrent infections. Proc Natl Acad Sci U S A. 1998;95:13125–13129.
   PubMed Web of Science ®Google Scholar
• Papp KA, Griffiths CEM, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168:844–854.
   PubMed Web of Science ®Google Scholar
• Papp K, Gottlieb AB, Naldi L, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol JDD. 2015;14:706–714.
   PubMed Web of Science ®Google Scholar